Identification of the peripheral blood levels of interleukin-12, interleukin-10, and transforming growth factor-β in patients with laryngeal squamous cell carcinoma

Head and Neck

Volumn 34, Issue 3, 2012, Pages 393-397

  Günaydin, Riza Önder ^a   Kesikli, Sacit Altuǧ ^a   Kansu, Emin ^a   Hoşal, Ali Şefik ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

IL 10; IL 12; larynx; SCC; TGF

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LARYNGEAL SQUAMOUS CELL CARCINOMA; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84856967527     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21738     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116: 1-13. (Pubitemid 44337830)
3. Cosetti M, Yu GP, Schantz SP,. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg 2008; 134: 370-379. (Pubitemid 351581084)
4. Müller-Hübenthal B, Azemar M, Lorenzen D, et al. Tumour biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res 2009; 29: 4795-4805.
5. Wan YY,. Multi-tasking of helper T cells. Immunology 2010; 130: 166-171.
6. Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146. (Pubitemid 37328691)
7. Lin WW, Karin M,. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183. (Pubitemid 46718402)
8. Melief CJ,. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-383.
9. Sorensen EW, Gerber SA, Frelinger JG, Lord EM,. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol 2010; 184: 1858-1866.
10. Salazar-Onfray F, López MN, Mendoza-Naranjo A,. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182. (Pubitemid 46401435)
11. Asadullah K, Sterry W, Volk HD,. Interleukin-10 therapyreview of a new approach. Pharmacol Rev 2003; 55: 241-269.
12. Vicari AP, Trinchieri G,. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev 2004; 202: 223-236. (Pubitemid 39576915)
13. Jakowlew SB,. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006; 25: 435-457. (Pubitemid 44922360)
14. Leivonen SK, Kähäri VM,. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007; 121: 2119-2124.
15. Wrzesinski SH, Wan YY, Flavell RA,. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 15: 5262-5270. (Pubitemid 47510349)
16. Shah JP,. Head and neck sites: larynx. In:, Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC cancer staging manual, 6th Edition. New York: Springer; 2002. pp 61-73.
17. Blankenstein T,. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005; 17: 180-186. (Pubitemid 40343106)
18. Kim R, Emi M, Tanabe K,. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 2005; 4: 924-933. (Pubitemid 41598585)
19. Pai SI, Westra WH,. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009; 4: 49-70.
20. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH,. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007; 7: 1705-1721. (Pubitemid 350157496)
21. Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A,. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol 2006; 28: 319-322. (Pubitemid 46226105)
22. O'Hara RJ, Greenman J, MacDonald AW, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998; 4: 1943-1948. (Pubitemid 28369179)
23. Zeimet AG, Widschwendter M, Knabbe C, et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J CLin Oncol 1998; 16: 1861-1868. (Pubitemid 28234733)
24. Derin D, Soydinc HO, Guney N, et al. Serum IL-8 and IL-12 levels in breast cancer. Med Oncol 2007; 24: 163-168. (Pubitemid 350135966)
25. Wojciechowska-Lacka A, Matecka-Nowak M, Adamiak E, Lacki JK, Cerkaska-Gluszak B,. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996; 43: 155-158. (Pubitemid 26229349)
26. Mustea A, Könsgen D, Braicu EI, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 2006; 26: 1715-1718.
27. Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ,. Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 2001; 136: 937-940.
28. Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007; 121: 246-252. (Pubitemid 46833125)
29. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR,. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004; 131: 573-576. (Pubitemid 39446277)
30. Lathers DM, Achille NJ, Young MR,. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003; 64: 1160-1166. (Pubitemid 37475277)
31. Zitvogel L, Tesniere A, Kroemer G,. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727. (Pubitemid 44453458)
32. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG,. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007; 56: 1687-1700. (Pubitemid 47313090)
33. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195. (Pubitemid 27297457)
34. Munn DH,. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006; 18: 220-225. (Pubitemid 43327306)
35. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM,. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001; 166: 5398-5406. (Pubitemid 32374159)
36. Zha Y, Blank C, Gajewski TF,. Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004; 24: 229-237. (Pubitemid 40052425)
37. Zou W,. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
38. Zou W,. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274. (Pubitemid 40488632)
39. Baird L, Terskikh A,. The tumor microenvironment. Adv Exp Med Biol 2010; 671: 67-73.
40. Pries R, Wollenberg B,. Cytokines in head and neck. Cytokine Growth Factor Rev 2006; 17: 141-146.
41. Nowak M, Glowacka E, Szpakowski M, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010; 31: 375-383.
42. Bergmann C, Strauss L, Zeidler R, et al. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67: 8865-8873. (Pubitemid 47437463)
43. Iwasaki A, Medzhitov R,. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295.